Destiny Pharma appoints Dr Debra Barker as Non-Executive Director

Link to Full Article Experienced pharmaceutical executive and medical director with expertise in anti-infective drug development and in-licensing Brighton, United Kingdom – 2 December 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs that address clear commercial opportunities and also address the global problem of […]

Dr Liam Brennan has joined the Board as the STFC Investor Director, replacing Dr Kate Ronayne.

Link to Full Article Liam is Head of Technology Transfer at The Science and Technology Facilities Council (STFC), part of UK Research and Innovation. STFC established The Electrospinning Company in 2010 and have invested and supported the Company since then. After completing his PhD, Liam co-founded and led a company to target an opportunity to […]

AVITA Medical Announces Institutional Placement of A$120.0 Million to Support Commercial Growth and Pipeline Development

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 13 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today an institutional placement of A$120.0 million (Institutional Placement) to fund pipeline development of new indications, […]

Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update

Link to Full Article MARINA DEL REY, Calif., Nov. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced third quarter results and provided a corporate and clinical update. Key Third Quarter and Subsequent Period Highlights: Announced development of […]

A fast and reliable method to reach a conclusive diagnosis of MYH9-related disorder

Link to Full Article Congenica platform provides variant review and assessment to support conclusive diagnoses for patients with complex and commonly misdiagnosed bleeding disorders in a large multicenter genomic study. MYH9-related disorder (MYH9-RD) is a complex condition that can have many signs and symptoms, including bleeding problems, hearing loss, kidney disease, and cataracts. The complexity […]

AVITA Medical Added to S&P/ASX 200 Index

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 8 November 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today that the company will be added to the S&P/ASX 200 index, effective upon market open […]

AVITA Medical Reports First Quarter Fiscal 2020 Financial Results and Company Update

Link to Full Article • U.S. RECELL® System product sales of A$4.6M for fiscal first quarter, 60% growth quarter-over-quarter • Over half of all U.S. burn centers and surgeons trained on RECELL System Valencia, Calif., USA, and Melbourne, Australia, 31 October 2019 — AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a […]

ARECOR AND JDRF SIGN A JOINT RESEARCH, DEVELOPMENT AND COMMERCIALISATION AGREEMENT TO DEVELOP A CO-FORMULATION INSULIN FOR THE TREATMENT OF DIABETES

Link to Full Article Cambridge, UK., 22 October 2019: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that it has signed a Research, Development and Commercialisation agreement with JDRF, the leading global organization funding type 1 diabetes (T1D) research. Under this collaboration, Arecor and JDRF will […]

Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive

Link to Full Article MARINA DEL REY, Calif., Oct. 21, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has received a Research and Development (R&D) Tax Incentive cash rebate of USD $1.3 million from the Australian Tax Office based on Armata’s […]

Positive results published from an independent (US National Institute of Health) XF-73 phase 1 clinical trial in a peer reviewed journal

Link to Full Article The publication in the Journal of Global Antimicrobial Resistance concluded that application of a nasal gel formulation of XF-73 in healthy volunteers was safe, well tolerated and generated minimal side effects Treatment with XF-73 was also associated with a rapid reduction in nasal Staphylococcus aureus in all subjects; nasal carriage of […]